Kymera Therapeutics (NASDAQ:KYMR) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Kymera Therapeutics (NASDAQ:KYMR) announced its quarterly earnings results on Thursday. The company reported ($0.82) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.01, Briefing.com reports. Kymera Therapeutics had a negative net margin of 178.27% and a negative return on equity of 28.88%. The firm had revenue of $3.74 million during the quarter, compared to analysts’ expectations of $10.34 million. During the same period in the prior year, the company earned ($0.90) EPS. The firm’s revenue was down 20.9% on a year-over-year basis.

Kymera Therapeutics Trading Up 0.6 %

NASDAQ KYMR traded up $0.30 during trading hours on Friday, reaching $46.47. The company’s stock had a trading volume of 412,696 shares, compared to its average volume of 597,304. The business has a 50-day simple moving average of $47.06 and a 200 day simple moving average of $40.57. Kymera Therapeutics has a 52 week low of $9.60 and a 52 week high of $53.27. The stock has a market cap of $2.87 billion, a PE ratio of -19.02 and a beta of 2.21.

Insider Activity

In related news, Director Jeffrey W. Albers sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $49.10, for a total transaction of $245,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, Director Pamela Esposito sold 13,500 shares of the firm’s stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total value of $651,780.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Jeffrey W. Albers sold 5,000 shares of the business’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $49.10, for a total value of $245,500.00. The disclosure for this sale can be found here. Corporate insiders own 15.82% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Guggenheim raised their target price on Kymera Therapeutics from $45.00 to $52.00 and gave the company a “buy” rating in a report on Friday. B. Riley lifted their target price on Kymera Therapeutics from $31.00 to $36.00 and gave the stock a “neutral” rating in a research report on Tuesday, July 9th. Wells Fargo & Company upped their target price on Kymera Therapeutics from $30.00 to $38.00 and gave the company an “equal weight” rating in a research report on Monday, August 12th. Morgan Stanley raised their price target on shares of Kymera Therapeutics from $34.00 to $45.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 14th. Finally, Truist Financial reaffirmed a “buy” rating and issued a $53.00 price target (down from $54.00) on shares of Kymera Therapeutics in a report on Friday. Four analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $49.15.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.